| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease J Sevigny, P Chiao, T Bussière, PH Weinreb, L Williams, M Maier, ... Nature 537, 50-56, 2016 | 2874 | 2016 |
| Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease S Budd Haeberlein, PS Aisen, F Barkhof, S Chalkias, T Chen, S Cohen, ... The Journal of Prevention of Alzheimer's Disease 9 (2), 197-210, 2022 | 548 | 2022 |
| Support Vector Hazards Machine: A Counting Process Framework for Learning Risk Scores for Censored Outcomes Y Wang, T Chen, D Zeng Journal of Machine Learning Research 17 (167), 1-37, 2016 | 317* | 2016 |
| Global gene expression analysis of the shoot apical meristem of maize (Zea mays L.) K Ohtsu, MB Smith, SJ Emrich, LA Borsuk, R Zhou, T Chen, X Zhang, ... The Plant Journal 52 (3), 391-404, 2007 | 178 | 2007 |
| Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease. HS Budd, J O'Gorman, P Chiao, T Bussière, P von Rosenstiel, Y Tian, ... The journal of prevention of Alzheimer's disease 4 (4), 255-263, 2017 | 130 | 2017 |
| Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials J Sevigny, J Suhy, P Chiao, T Chen, G Klein, D Purcell, J Oh, A Verma, ... Alzheimer Disease & Associated Disorders 30 (1), 1-7, 2016 | 114 | 2016 |
| Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease J Sevigny, P Chiao, T Bussière, PH Weinreb, L Williams, M Maier, ... Nature 546 (7659), 564-564, 2017 | 84 | 2017 |
| Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab P Chiao, BJ Bedell, B Avants, AP Zijdenbos, M Grand'Maison, P O’Neill, ... Journal of Nuclear Medicine 60 (1), 100-106, 2019 | 57 | 2019 |
| Emerge and Engage topline results: Phase 3 studies of aducanumab in early Alzheimer’s disease: Developments in clinical trials and cognitive assessment SB Haeberlein, C von Hehn, Y Tian, S Chalkias, KK Muralidharan, ... Alzheimer's & Dementia 16, e047259, 2020 | 51 | 2020 |
| O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind … J Sevigny, P Chiao, L Williams, T Chen, Y Ling, J O'Gorman, C Hock, ... Alzheimer's & Dementia 11 (7S_Part_6), P277-P277, 2015 | 42 | 2015 |
| Pros and cons of prostate cancer screening: Associations with screening knowledge and attitudes among Urban African American men SN Davis, MA Diefenbach, HB Valdimarsdottir, T Chen, SJ Hall, ... Journal of the National Medical Association 102 (3), 174-82, 2010 | 32 | 2010 |
| Multiple Kernel Learning with Random Effects for Predicting Longitudinal Outcomes and Data Integration T Chen, D Zeng, Y Wang Biometrics 71 (4), 918-928, 2015 | 22 | 2015 |
| Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington’s Disease T Chen, Y Wang, Y Ma, K Marder, DR Langbehn Journal of Probability and Statistics 2012 (doi:10.1155/2012/375935 …, 2012 | 12 | 2012 |
| Targeted Local Support Vector Machine for Age-Dependent Classification T Chen, Y Wang, H Chen, K Marder, D Zeng Journal of the American Statistical Association 109 (507), 1174-1187, 2014 | 10 | 2014 |
| Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4. 1-001) C von Hehn, P von Rosenstiel, Y Tian, S Wu, T Chen, LA Skordos, ... Neurology 92 (15 Supplement), 2019 | 8 | 2019 |
| Growth of a Scientific Community of Practice Public Health Services and Systems Research JA Merrill, JW Keeling, RV Wilson, TV Chen American Journal of Preventive Medicine 41 (1), 100-104, 2011 | 8 | 2011 |
| Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2. 004) SB Haeberlein, S Gheuens, T Chen, J O’Gorman, P von Rosenstiel, ... Neurology 90 (15 Supplement), 2018 | 7 | 2018 |
| O1‐09‐06: 24‐MONTH ANALYSIS OF CHANGE FROM BASELINE IN CLINICAL DEMENTIA RATING SCALE COGNITIVE AND FUNCTIONAL DOMAINS IN PRIME: A RANDOMIZED PHASE 1B STUDY OF THE ANTI–AMYLOID … SB Haeberlein, C Castrillo-Viguera, S Gheuens, T Chen, J O'Gorman, ... Alzheimer's & Dementia 14 (7S_Part_4), P242-P242, 2018 | 6 | 2018 |
| Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled phase 1b study in patients with prodromal or mild Alzheimer’s … P von Rosenstiel, S Gheuens, T Chen, J O’Gorman, P Chiao, G Wang, ... Neurology 90 (15 Supplement), 2018 | 4 | 2018 |
| Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled phase 1b study in patients with prodromal or mild Alzheimer’s … P von Rosenstiel, S Gheuens, T Chen, J O’Gorman, P Chiao, G Wang, ... Neurology 90 (15 Supplement), 2018 | 4 | 2018 |
Huaihou ChenUniversity of FloridaVerified email at nyumc.org
Huaihou ChenUniversity of FloridaVerified email at nyumc.org